Around 130 patients will be randomized with either OGX-427 or placebo in combination with ABRAXANE and gemcitabine therapy in the investigator-sponsored, placebo-controlled trial.
The primary endpoint is overall survival while progression-free survival (PFS), tumor response rates, safety, tolerability, and the effect of therapy on heat shock protein (Hsp27) levels will also be assessed.
The University of California, San Francisco, division of hematology/oncology associate professor of medicine and trial primary investigator Andrew Ko said, "The Rainier trial provides us the opportunity to explore the role of Hsp27 in pancreatic cancer, and the potential ability of OGX-427 to improve on clinical outcomes when added to combination chemotherapy."
The Sarah Cannon Research Institute (SCRI) is sponsoring the trial that is scheduled to be conducted at around 12 sites in the US.